A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines
Sign Up to like & getrecommendations! Published in 2022 at "Vaccines"
DOI: 10.3390/vaccines11010002
Abstract: Administration of PCSK9-specific monoclonal antibodies, as well as peptide-based PCSK9 vaccines, can lower plasma LDL cholesterol by blocking PCSK9. However, these treatments also cause an increase in plasma PCSK9 levels, presumably due to the formation… read more here.
Keywords: peptide based; full length; cvlp based; pcsk9 ... See more keywords